REPL vs. RNA, ADMA, ACLX, AKRO, RYTM, SRRK, IMVT, APLS, VKTX, and ACAD
Should you be buying Replimune Group stock or one of its competitors? The main competitors of Replimune Group include Avidity Biosciences (RNA), ADMA Biologics (ADMA), Arcellx (ACLX), Akero Therapeutics (AKRO), Rhythm Pharmaceuticals (RYTM), Scholar Rock (SRRK), Immunovant (IMVT), Apellis Pharmaceuticals (APLS), Viking Therapeutics (VKTX), and ACADIA Pharmaceuticals (ACAD). These companies are all part of the "pharmaceutical products" industry.
Replimune Group vs.
Replimune Group (NASDAQ:REPL) and Avidity Biosciences (NASDAQ:RNA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, community ranking, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.
In the previous week, Replimune Group had 10 more articles in the media than Avidity Biosciences. MarketBeat recorded 13 mentions for Replimune Group and 3 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 0.85 beat Replimune Group's score of 0.00 indicating that Avidity Biosciences is being referred to more favorably in the news media.
92.5% of Replimune Group shares are held by institutional investors. 8.8% of Replimune Group shares are held by company insiders. Comparatively, 3.7% of Avidity Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Replimune Group has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500. Comparatively, Avidity Biosciences has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.
Replimune Group presently has a consensus target price of $19.29, indicating a potential upside of 37.17%. Avidity Biosciences has a consensus target price of $65.80, indicating a potential upside of 103.70%. Given Avidity Biosciences' higher probable upside, analysts clearly believe Avidity Biosciences is more favorable than Replimune Group.
Replimune Group received 10 more outperform votes than Avidity Biosciences when rated by MarketBeat users. However, 67.81% of users gave Avidity Biosciences an outperform vote while only 63.88% of users gave Replimune Group an outperform vote.
Replimune Group has a net margin of 0.00% compared to Avidity Biosciences' net margin of -2,772.45%. Avidity Biosciences' return on equity of -27.66% beat Replimune Group's return on equity.
Avidity Biosciences has higher revenue and earnings than Replimune Group. Avidity Biosciences is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.
Summary
Replimune Group and Avidity Biosciences tied by winning 9 of the 18 factors compared between the two stocks.
Get Replimune Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Replimune Group Competitors List
Related Companies and Tools
This page (NASDAQ:REPL) was last updated on 2/21/2025 by MarketBeat.com Staff
Free REPL Stock Alerts